Niner Pharmaceuticals Expands into High-Purity Peptide Segment for Metabolic Health; Announces R&D for AI-Driven Ambientera Solution
Jan 19, 2026
Hyderabad (Telangana) [India], January 19: Niner Pharmaceuticals LLC has announced a major strategic expansion into the global high-purity peptide segment, shifting its focus beyond regulated supply chains to emphasize molecular innovation. The company aims to position these high-purity molecules as foundational tools for metabolic health, longevity, and recovery. In conjunction with this pharmaceutical expansion, the company has also disclosed that it is currently in the research and development phase for Ambientera, a new AI-driven home solution and residential operating system expected to launch next year.